Mark Ray’s Post

Second Primary Breast Cancer in Young Breast Cancer Survivors https://ja.ma/45uBcqp

**Increased Breast Cancer Risk in Women with Primary Ovarian Insufficiency (POI)** -A recent study highlights an increased risk of breast cancer among women diagnosed with Primary Ovarian Insufficiency (POI). - The majority of breast cancer cases were invasive ductal (93%) and estrogen receptor-positive (77%).  -28% never took HRT, and only 11% used HRT after age 50. - Genetic testing in a small subset showed no pathogenic mutations, though one woman had a BRIP1 variant of uncertain significance. - 89% of the women had a family history of various cancers. This study underscores the importance of careful monitoring and personalized care for women with POI, particularly in terms of breast cancer risk. OncoDaily OncoAlert #BreastCancerAwareness #OncologyResearch

🚀 Excited to share our latest publication: "Functional Analysis of BRCA1 3'UTR Variants Predisposing to Breast Cancer"! 🔬 We explored the impact of specific 3'UTR variants on BRCA1 expression, focusing on two variants identified through Whole Exome Sequencing of 400 breast cancer patients. Our findings reveal that one variant, c.*36C>G, appears to disrupt miRNA interaction, leading to increased BRCA1 expression in certain breast cancer cell lines. 🌟 Notably, this variant may offer protection against Triple Negative Breast Cancer, aligning with clinical observations in HR+ patients. A huge step forward in understanding genetic factors in breast cancer risk and progression! 👉 https://lnkd.in/eMHhrXFM #BreastCancerResearch #Genetics #BRCA1 #CancerScience #WomensHealth

In an article for TODAY, Maura Hohman highlights Jill Martin's important message during Breast Cancer Awareness Month. Jill, a breast cancer survivor, wants to encourage women to get checked regularly. Last year, she was diagnosed with Stage 2 breast cancer after genetic testing revealed she carries a BRCA mutation, which significantly increases the risk of developing breast cancer. Her cancer was only discovered during an MRI conducted prior to a planned preventive surgery, emphasizing the importance of understanding one’s health risks and the value of genetic testing. Jill stresses the need for genetic testing, especially for those with a family history of certain cancers. According to Dr. Susan Domchek from the Penn Medicine Basser Center for BRCA, individuals with early-onset breast cancer, ovarian cancer, or those with a family history of these conditions should consider testing. The National Cancer Institute (NCI) also recommends that anyone with a strong family history of cancer speak with a healthcare provider about their options. This proactive approach can help individuals make informed decisions about their health and any necessary preventive measures. Jill's journey illustrates how knowledge can save lives. She underwent a double mastectomy, removal of her ovaries and fallopian tubes, and completed radiation and chemotherapy to reduce her risk of recurrence. By raising awareness about genetic testing and its importance, Jill hopes to inspire others to discover their own risks and take steps to protect their health. Morehouse General Hospital is also urging women to get checked, reinforcing that early detection can make a significant difference. #BreastCancerAwarenessMonth #GeneticTesting #HealthCheck #FightCancer #NationalCancerInstitute #MorehouseGeneralHospital https://lnkd.in/dzmD_ume

Breast Cancer Awareness Alert! Did you know that your genetics play a vital role in your breast cancer risk? BRCA mutations and other genetic factors can significantly impact your likelihood of developing breast cancer. Understanding these risks isn't just for awareness—it's a step towards prevention and proactive health decisions. 💪 Click the link to discover how genetics influences breast cancer, what BRCA mutations mean, and the options available for those at risk. Empower yourself with knowledge! Naveen Sanchety Click the link to read the full article: https://bit.ly/4e8pxA9 #sarvodayahealthcare #bestmultispecialityhospital #breastcancer #breastcancerawareness #breastcancerrisk

Dr. Aliabadi, who discovered Olivia Munn’s breast cancer, talks with PEOPLE Magazine | PEOPLE.com about the importance of understanding the tools available to assess breast cancer risk, including the MyRisk Hereditary Cancer Test with RiskScore.   “If you have a family history of cancer, “it's important to talk to your doctor about genetic cancer testing,” says Aliabadi, whose office recommends patients starting at age 25 take the MyRisk Hereditary Cancer Test, which includes free genetic counseling and evaluates 48 genes associated with hereditary cancer risk.” Read the full article: https://brnw.ch/21wIUxZ #BreastCancer #RiskAssessment

Two important studies published today that will add to the momentum in changing how we screen for colorectal cancer. As the editorial (3rd link) astutely points out, the best screening test is the one that is "actually performed" and, in the US, screening adherence is below recommended, presumably because screening involves a colonoscopy (while in other countries recommended screening is via a stool test for hemoglobin called FIT). In the new studies, testing incorporates DNA based testing, one deriving DNA from stool samples and the other from blood. The good news is that both improve on the sensitivity of current non-invasive testing (FIT test) while approaching the specificity of that test. Obviously, catching cancer before it causes even microscopic bleeding is highly desirable. Importantly, unlike colonoscopy, these are not diagnostic tests but rather are screening tests to be viewed as gatekeepers to colonoscopy (similar in that respect to non-invasive prenatal screening which prompts amniocentesis or CVS). In general, for screening to be more effective, we also need to move beyond using age alone as the qualification criterion for screening. We know some people are at greater genetic or environmental risk. Having a simple age cutoff for an entire population makes no sense. If you are interested in more technical aspects of cell free DNA, also see the very nice explainer editorial from one of its pioneers, Dennis Lo (4th link). https://lnkd.in/gwRkh_dZ https://lnkd.in/gZ6bHnyE https://lnkd.in/g6yVPSYZ https://lnkd.in/gRs5Jn-R

Should we be moving from 'one-size-fits-all' to personalised screening schedules? This research underscores the power of integrating Polygenic Risk Scores (PRS), family history, and pathogenic variants in breast cancer. Utilising the robust FinnGen database, the study reveals that women with high PRS exhibit an increased risk of developing breast cancer, comparable to those with known genetic mutations and family history. Moving forward, we need to: 1. Integrate PRS into routine risk assessments to tailor individual screening strategies. 2. Consider earlier screening for those with high PRS and potentially extend intervals for those at lower risk. 3. Leverage real-world data to refine screening guidelines and personalise patient care. This paves the way towards precision medicine in breast cancer, ensuring early detection and optimal resource allocation while reducing over-screening for low-risk individuals. #BreastCancerScreening #PrecisionMedicine #Genomics #HealthcareInnovation #LinkMedicalSolutions https://lnkd.in/eqeK3qvy

At Myriad Genetics we continue to fulfill our goal to mitigate cancer risks. This is a great article highlighting the impact of Myriads Myrisk with Riskscore for All Ancestries!

At Myriad Genetics we continue to fulfill our goal to mitigate cancer risks. This is a great article highlighting the impact of Myriads Myrisk with Riskscore for All Ancestries!